Kwality Pharmaceuticals Raises FY27 Revenue Guidance to Rs 720 Crore
Key highlights
- Kwality Pharmaceuticals reported Q2 FY27 revenue of Rs 181.2 crore, up 62% year-on-year.
- Q2 FY27 EBITDA rose 96% year-on-year to Rs 49.8 crore, with a 27.5% margin.
- FY27 revenue guidance was increased to Rs 720 crore-plus from Rs 700 crore-plus.
- H1 FY27 revenue stood at Rs 343 crore, while FY26 revenue was Rs 503 crore.
powered by IRIS

Kwality Pharmaceuticals Limited raised its FY27 revenue guidance to Rs 720 crore-plus after reporting Q2 FY27 revenue of Rs 181.2 crore, up 62% year-on-year, alongside a 27.5% EBITDA margin. The revised outlook is important because it implies growth of more than 43% over FY26 revenue of Rs 503 crore.
Know Kwality Pharmaceuticals inside out
Results, valuation, peers and who's buying, in one view.
Why did Kwality Pharmaceuticals raise its FY27 revenue guidance?
Kwality Pharmaceuticals raised its FY27 revenue guidance from Rs 700 crore-plus to Rs 720 crore-plus following strong Q2 and first-half performance. Management cited business momentum and an accelerating pace of product registrations while communicating the revised outlook during its earnings call held on November 13, 2026.
The company reported Q2 FY27 revenue of Rs 181.2 crore, compared with Rs 111 crore in Q2 FY26. That represented 62% year-on-year growth and 12% sequential growth from Rs 162.4 crore in Q1 FY27. For H1 FY27, revenue stood at Rs 343 crore.
The revised guidance also follows management's focus on product launches and registrations in its operating markets. The company said that FY27 growth would depend on registrations, product launches and planned expansion. Management additionally said that Rs 750 crore was achievable, while the formal guidance remained at Rs 720 crore-plus.
The Q2 FY27 earnings conference call was hosted by Go India Advisors LLP. Kwality Pharmaceuticals has also made the audio recording of the call, covering the quarter and half year ended September 30, 2026, available on its website.
How did Kwality Pharmaceuticals perform in Q2 FY27?
Kwality Pharmaceuticals reported broad operating growth in Q2 FY27, with EBITDA rising 96% year-on-year to Rs 49.8 crore and gross profit increasing 67% to Rs 94.5 crore. EBITDA margin was 27.5%, reflecting the reported improvement in operating leverage and product mix.
The investor presentation reported profit after tax of Rs 29 crore for Q2 FY27, compared with Rs 14.1 crore in the corresponding quarter of the previous year. Management's call remarks also referred to profit after tax doubling, though a separate transcript reported a different absolute figure. The presentation's reported quarterly figure is used in the comparison below.
Management has maintained its target of absolute EBITDA margins in the 27% to 28% range. Its FY27 framework includes EBITDA of Rs 189 crore to Rs 196 crore-plus at a margin of 27% to 28%-plus, and profit after tax of Rs 122 crore-plus.
Got a follow-up? Ask IRIS
What are Kwality Pharmaceuticals' main growth drivers?
Kwality Pharmaceuticals identified export momentum, new product launches, biologics commercialisation and European GMP certifications as key elements of its growth plan. The company also described its product pipeline and registration activity as important to the pace of future revenue growth.
Exports are central to the operating model described on the call. Management said India as an end market accounts for about 4% to 5% of revenue. It added that a substantial share of domestic billing represents sales to Indian partners that subsequently export products.
The company also discussed its procurement profile. According to management, about 85% of procurement is from India, while China accounts for roughly 10% to 15%. These details provide context on the company's supply sourcing as it pursues higher sales volumes.
Kwality Pharmaceuticals has set a revenue target of Rs 1,000 crore-plus by FY29. That target is dependent on the execution of its stated plans, including commercialisation, approvals and launches, rather than being a reported financial result.
What does the revised outlook mean for investors and operations?
Kwality Pharmaceuticals' revised FY27 guidance indicates that management expects the Q2 growth momentum to support revenue of at least Rs 720 crore for the full year. Compared with FY26 revenue of Rs 503 crore, this implies growth of more than 43% based on the company's stated guidance.
For investors, the relevant reported indicators are the 62% rise in quarterly revenue, the 27.5% EBITDA margin and the increase in full-year guidance. The company has also retained its 27% to 28% absolute EBITDA margin range, making margin delivery a material operating measure alongside sales growth.
The call provided no share-price information or financial-market reaction. It also did not disclose specific launch dates, individual product contributions or a detailed country-wise revenue split. As a result, the available information supports the company's stated growth plan but does not establish the timing or value of individual future opportunities.
For customers and distribution partners, registrations and product launches remain operationally relevant because management linked them directly to the pace of growth. For the pharmaceutical sector, the update highlights the role of export markets, certification and product approvals in the company's reported strategy.
Conclusion
Kwality Pharmaceuticals delivered Q2 FY27 revenue of Rs 181.2 crore, EBITDA of Rs 49.8 crore and a 27.5% EBITDA margin, prompting an increase in FY27 revenue guidance to Rs 720 crore-plus. The quarter also placed the company's FY29 revenue target of Rs 1,000 crore-plus in the context of continued export-led growth, registrations and product launches.
The next points to watch are the company's execution against the Rs 720 crore-plus FY27 guidance, its ability to sustain the stated 27% to 28% EBITDA margin range, and progress on registrations, launches, biologics commercialisation and European GMP certifications that management has identified as growth drivers.


